Gnat S, Łagowski D, Nowakiewicz A, Dyląg M. A global view on fungal infections in humans and animals: opportunistic infections and microsporidioses. J Appl Microbiol. John Wiley and Sons Inc; 2021. pp. 2095–113.

WHO fungal priority. Pathogens list to guide research, development and public health action. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO.

Google Scholar 

Watkins RR, Gowen R, Lionakis MS, Ghannoum M. Update on the Pathogenesis, virulence, and treatment of Candida Auris. Pathog Immun. 2022;7:46–65.

Article  PubMed  PubMed Central  Google Scholar 

Munshi A, Almadani F, Ossenkopp J, Alharbi M, Althaqafi A, Alsaedi A, et al. Risk factors, antifungal susceptibility, complications, and outcome of Candida Auris bloodstream infection in a tertiary care center in the western region of Saudi Arabia. J Infect Public Health. 2024;17:182–8.

Article  PubMed  Google Scholar 

Hoenigl M, Seidel D, Sprute R, Cunha C, Oliverio M, Goldman GH et al. COVID-19-associated fungal infections. Nat Microbiol Nat Res. 2022. pp. 1127–40.

Tsai CS, Lee SSJ, Chen WC, Tseng CH, Lee NY, Chen PL, et al. COVID-19-associated candidiasis and the emerging concern of Candida Auris infections. J Microbiol Immunol Infect. Elsevier Ltd; 2023. pp. 672–9.

Lankarani KB, Akbari M, Tabrizi R, Vali M, Sekhavati E, Heydari ST, et al. Candida auris: outbreak fungal pathogen in COVID-19 pandemic: a systematic review and meta-analysis Iran J Microbiol. 2022;14(3):276–84. https://doi.org/10.1128/AAC.01181-21.

Riera FO, Caeiro JP, Angiolini SC, Vigezzi C, Rodriguez E, Icely PA, et al. Invasive candidiasis: Update and Current challenges in the management of this mycosis in South America. Antibiotics. MDPI; 2022.

Agnelli C, Valerio M, Bouza E, Us Guinea J, Sukiennik T, Guimar T, et al. Prognostic factors of Candida spp. bloodstream infection in adults: a nine-year retrospective cohort study across tertiary hospitals in Brazil and Spain articles research in context. Lancet Reg Health Am. 2022;6:100117. https://doi.org/10.1016/j.lana.2021.100117.

Escandón P, Lockhart SR, Chow NA, Chiller TM. Candida Auris: a global pathogen that has taken root in Colombia. Biomedica. Instituto Nacional de Salud; 2023. pp. 278–87.

Sanyaolu A, Okorie C, Marinkovic A, Abbasi AF, Prakash S, Mangat J, et al. Candida Auris: an overview of the emerging drug-resistant fungal infection. Infect Chemother. 2022;236–46.

Marena GD, Carvalho GC, Monazzi LCS, Maschio-Lima T, De Almeida MTG, Da Silva JLM, et al. Infection caused by Candida Auris: state of the art. Mycosphere. 2022;13:820–61.

Article  Google Scholar 

Gómez-Gaviria M, Martínez-álvarez JA, Chávez-Santiago JO, Mora-Montes HM. Candida Haemulonii Complex and Candida Auris: Biology, virulence factors, Immune Response, and Multidrug Resistance. Infect drug resist. Dove Medical Press Ltd; 2023. pp. 1455–70.

Kim HY, Nguyen TA, Kidd S, Chambers J, Alastruey-Izquierdo A, Shin JH, et al. Candida auris —a systematic review to inform the world health organization fungal priority pathogens list. Med Mycol. 2024;62(6):myae04262. https://doi.org/10.1093/mmy/myae042.

Pericolini E, Roselletti E, De Gaetano S, Midiri A, Mancuso G, Avola MG, et al. Microorganisms Candida auris Outbreaks: current status and future perspectives. Microoganisms. 2024;12(5):927. https://doi.org/10.3390/microorganisms12050927.

Mishra SK, Yasir M, Willcox M. Candida Auris: an emerging antimicrobial-resistant organism with the highest level of concern. Lancet microbe. Elsevier Ltd; 2023. pp. e482–3.

Ganeshkumar A, Muthuselvam M, de Lima PMN, Rajaram R, Junqueira JC. Current perspectives of antifungal therapy: a special focus on Candida Auris. J Fungi. 2024;10:408.

Article  CAS  Google Scholar 

Suphavilai C, Ko KKK, Lim KM, Tan MG, Boonsimma P, Chu JJK, et al. Detection and characterisation of a sixth Candida auris clade in Singapore: a genomic and phenotypic study. Lancet Microbe. 2024;(9):100878.

Akinbobola AB, Kean R, Hanifi SMA, Quilliam RS. Environmental reservoirs of the drug-resistant pathogenic yeast Candida Auris. PLoS Pathog. Public Library of Science; 2023.

Casadevall A, Kontoyiannis DP, Robert V. On the emergence of candida Auris: climate change, azoles, swamps, and birds. mBio. 2019;10.

Arora P, Singh P, Wang Y, Yadav A, Pawar K, Singh A, et al. Environmental isolation of candida Auris from the coastal wetlands of Andaman islands, India. mBio. 2021;12:1–9.

Article  Google Scholar 

Chowdhary A, Jain K, Chauhan N. Annual review of microbiology candida auris genetics and emergence. Annu Rev Microbiol. 2023;77:2023.

Huang X, Hurabielle C, Drummond RA, Bouladoux N, Desai JV, Sim CK, et al. Murine model of colonization with fungal pathogen Candida Auris to explore skin tropism, host risk factors and therapeutic strategies. Cell Host Microbe. 2021;29:210–e2216.

Article  PubMed  CAS  Google Scholar 

Pandya N, Cag Y, Pandak N, Pekok AU, Poojary A, Ayoade F et al. International Multicentre study of candida auris infections. J Fungi. 2021;7.

Alshahrani FS, Elgujja AA, Alsubaie S, Ezreqat SA, Albarraq AM, Barry M, et al. Description of Candida auris occurrence in a tertiary health institution in Riyadh, Saudi Arabia. Health (Basel). 2023;11(24):3150.

Naicker SD, Maphanga TG, Chow NA, Allam M, Kwenda S, Ismail A, et al. Clade distribution of Candida Auris in South Africa using whole genome sequencing of clinical and environmental isolates. Emerg Microbes Infect. 2021;10:1300–8.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ruiz-Gaitán A, Moret AM, Tasias-Pitarch M, Aleixandre-López AI, Martínez-Morel H, Calabuig E, et al. An outbreak due to Candida Auris with prolonged colonisation and candidaemia in a tertiary care European hospital. Mycoses. 2018;61:498–505.

Article  PubMed  Google Scholar 

https://www.cdc.gov/candida-auris/prevention/index.html. Centers for disease control and Prevention, CDC 2024. 2024.

Rabaan AA, Eljaaly K, Alfouzan WA, Mutair AA, Alhumaid S, Alfaraj AH, et al. Psychogenetic, genetic and epigenetic mechanisms in Candida auris: role in drug resistance. J Infect Public Health. 2023;257–63.

Chow NA, De Groot T, Badali H, Abastabar M, Chiller TM, Meis JF. Potential fifth clade of Candida Auris, Iran, 2018. Emerg Infect Dis. 2019;25:1780–1.

Article  PubMed  PubMed Central  Google Scholar 

Muñoz JF, Gade L, Chow NA, Loparev VN, Juieng P, Berkow EL, et al. Genomic insights into multidrug-resistance, mating and virulence in Candida Auris and related emerging species. Nat Commun. 2018;9(1):5346.

Chow NA, Muñoz JF, Gade L, Berkow EL, Li X, Welsh RM et al. Tracing the evolutionary history and global expansion of candida Auris using population genomic analyses. mBio. 2020;11(2):e03364-19.

Pan American Health Organization (PAHO). Epidemiological Alert Candida auris outbreaks in health care services in the context of the COVID-19 pandemic. 2021.

Calvo B, Melo ASA, Perozo-Mena A, Hernandez M, Francisco EC, Hagen F, et al. First report of Candida Auris in America: clinical and microbiological aspects of 18 episodes of candidemia. J Infect. 2016;73:369–74.

Article  PubMed  Google Scholar 

Moreno MV, Simian ME, Villarroel J, Fuenzalida LM, Yarad MF, Soto A, et al. Primer aislamiento de Candida auris en Chile. Revista chilena de infectología. 2019;36(6):767–73.

Garcia-Effron BG. The rising threat of intrinsically resistant Candida species in Argentina. Rev Argent Microbiol. 2023;55:201–3.

PubMed  Google Scholar 

de Almeida JN, Francisco EC, Hagen F, Brandão IB, Pereira FM, Presta Dias PH, et al. Emergence of candida Auris in Brazil in a covid-19 intensive care unit. J Fungi. 2021;7(3):220.

de Melo CC, de Sousa BR, da Costa GL, Oliveira MME, de Lima-Neto RG. Colonized patients by Candida Auris: third and largest outbreak in Brazil and impact of biofilm formation. Front Cell Infect Microbiol. 2023;13

Agência Nacional de Vigilância Sanitária, ANVISA. Confirmação de caso de Candida auris em Hospital de São Paulo. 2023. https://www.gov.br/anvisa/pt-br/centraisdeconteudo/publicacoes/servicosdesaude/comunicados-de-risco-1/alerta-candida-auris-em-sp-09-06-2023.pdf.

Secretaria de Estado de Saúde de Minas Gerais. Candida auris: funed realiza exames sob suspeita da infecção. 2024. https://www.saude.mg.gov.br/cidadao/banco-de-noticias/story/20456-candida-auris.

Nelson R. Emergence of resistant Candida Auris. Lancet Microbe. 2023;4:e396.

Article  PubMed  Google Scholar 

Pristov KE, Ghannoum MA. Resistance of Candida to azoles and echinocandins worldwide. Clinical Microbiology and infection. 2019;792–8.

Jacobs SE, Jacobs JL, Dennis EK, Taimur S, Rana M, Patel D, et al. Candida Auris Pan-drug-resistant to four classes of Antifungal agents. Antimicrob Agents Chemother. 2022;66(7):e0005322.

Marena GD, Ramos MA dos, Bauab S, Chorilli TMM. A critical review of analytical methods for quantification of amphotericin B in biological samples and pharmaceutical formulations. Crit Rev Anal Chem. 2022;555–76.

Janik S, Luchowski R, Grela E, Grudzinski W, Gruszecki WI. How does the antibiotic amphotericin B enter membranes and what does it do there? J Phys Chem Lett. 2024;15:4823–7.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Frías-De-león MG, Hernández-Castro R, Vite-Garín T, Arenas R, Bonifaz A, Castañón-Olivares L, et al. Antifungal resistance in Candida Auris: molecular determinants. Antibiotics. 2020;1–16.

Lockhart SR. Candida Auris and multidrug resistance: defining the new normal. Fungal Genetics and Biology. 2019;131:103243.

Lee Y, Robbins N, Cowen LE. Molecular mechanisms governing antifungal drug resistance. Npj Antimicrobials Resist. 2023;1:5.

Marena GD, dos Santos Ramos MA, Bauab TM, Chorilli M. Biological Properties and analytical methods for micafungin: a critical review. Crit Rev Anal Chem. 2021;312–28.

Jangir P, Kalra S, Tanwar S, Bari VK. Azole resistance in Candida Auris: mechanisms and combinatorial therapy. APMIS. 2023;442–62.

Wiederhold NP, Najvar LK, Olivo M, Morris KN, Patterson HP, Catano G, et al. Ibrexafungerp demonstrates in vitro activity against fluconazole-resistant candida auris and in vivo efficacy with delayed initiation of therapy in an experimental model of invasive candidiasis. Antimicrob Agents Chemother. 2021;65(6):e02694-20. https://doi.org/10.1128/AAC.02694-20.

Arendrup MC, Jørgensen KM, Hare RK, Chowdhary A. In vitro activity of ibrexafungerp (SCY-078) against Candida auris isolates as determined by EUCAST methodology and comparison with activity against C. albicans and C. glabrata and with the activities of six comparator agents. Antimicrob Agents Chemother. 2020;64(3):e02136-19. https://doi.org/10.1128/AAC.02136-19

Cidara therapeutics and. Melinta therapeutics announce FDA approval of rezzayo™ (rezafungin for injection) for the treatment of candidemia and invasive candidiasis. https://www.cidara.com/news/cidara-therapeutics-and-melinta-therapeutics-announce-fda-approval-of-rezzayo-rezafungin-for-injection-for-the-treatment-of-candidemia-and-invasive-candidiasis/

Helleberg M, Jørgensen KM, Hare RK, Datcu R, Chowdhary A, Arendrup MC. Rezafungin in vitro activity against contemporary nordic clinical candida isolates and Candida Auris determined by the EUCAST reference method. Antimicrob Agents Chemother. 2020;64.

Kovács R, Tóth Z, Locke JB, Forgács L, Kardos G, Nagy F, et al. Comparison of in vitro killing activity of rezafungin, anidulafungin, caspofungin, and micafungin against four candida auris clades in rpmi-1640 in the absence and presence of human serum. Microorganisms. 2021;9(4):863.

John LLH, Thomson DD, Bicanic T, Hoenigl M, Brown AJP, Harrison TS, et al. Heightened efficacy of Anidulafungin when used in combination with manogepix or 5-Flucytosine against Candida Auris in vitro. Antimicrob Agents Chemother. 2023;67(6):e0164522.

Arendrup MC, Chowdhary A, Jørgensen KM, Meletiadis J. Manogepix (APX001A) in vitro activity against Candida auris: head-to-head comparison of EUCAST and CLSI MICs. Antimicrob Agents Chemother. 2020;64(10):e00656-20. https://doi.org/10.1128/AAC.00656-20.

Rudramurthy SM, Colley T, Abdolrasouli A, Ashman J, Dhaliwal M, Kaur H, et al. In vitro antifungal activity of a novel topical triazole PC945 against emerging yeast Candida Auris. J Antimicrob Chemother. 2019;74:2943–9.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wiederhold NP, Lockhart SR, Najvar LK, Berkow EL, Jaramillo R, Olivo M, et al. The fungal Cyp51-Specific inhibitor VT-1598 demonstrates in Vitro and in vivo activity against Candida Auris. Antimicrob Agents Chemother. 2019;63(3):e02233-18.

Wiederhold NP, Najvar LK, Jaramillo R, Olivo M, Patterson H, Connell A, et al. The novel arylamidine T-2307 demonstrates in vitro and in vivo activity against Candida Auris. Antimicrob Agents Chemother. 2020;64(3):e02198-19.

Salama EA, Eldesouky HE, Elgammal Y, Abutaleb NS, Seleem MN. Lopinavir and ritonavir act synergistically with azoles against Candida Auris in vitro and in a mouse model of disseminated candidiasis. Int J Antimicrob Agents. 2023;62(3):106906.

Eldesouky HE, Salama EA, Lanman NA, Hazbun TR, Seleem MN. Potent synergistic interactions between lopinavir and azole antifungal drugs against emerging multidrug-resistant candida auris. Antimicrob Agents Chemother. 2021;65(1):e00684-20.

Elgammal Y, Salama EA, Seleem MN. Enhanced antifungal activity of posaconazole against Candida Auris by HIV protease inhibitors, atazanavir and saquinavir. Sci Rep. 2024;14(1):1571.

Halliday C, Kim HY, Tay E, Chen SCA, Alffenaar JW. Exploring synergy between azole antifungal drugs and statins for Candida Auris. J Antimicrob Chemother. 2023;78:2824–9.

Article  PubMed  PubMed Central  Google Scholar 

de-la-Fuente I, Guridi A, Jauregizar N, Eraso E, Quindós G, Sevillano E. In Vitro and in vivo activity of citral in combination with amphotericin B, anidulafungin and fluconazole against Candida Auris isolates. J Fungi. 2023;9(6):648.

Wiederhold NP, Najvar LK, Shaw KJ, Jaramillo R, Patterson H, Olivo M, et al. Efficacy of delayed therapy with fosmanogepix (APX001) in a murine model of candida auris invasive candidiasis. Antimicrob Agents Chemother. 2019;63(11):e01120-19.

Nagy F, Vitális E, Jakab Á, Borman AM, Forgács L, Tóth Z, et al. In vitro and in vivo effect of exogenous farnesol exposure against Candida Auris. Front Microbiol. 2020;11:957.

Zhang F, Zhao M, Braun DR, Ericksen SS, Piotrowski JS, Nelson J et al. A marine microbiome antifungal targets urgent-threat drug-resistant fungi. Science (1979). 2020;370:974–8.

Xin H, Rosario-Colon JA, Eberle K. Novel intravenous immunoglobulin therapy for the prevention and treatment of Candida Auris and candida albicans disseminated candidiasis. mSphere. 2023;8(1):e0058422.

Kumari A, Tripathi AH, Gautam P, Gahtori R, Pande A, Singh Y, et al. Adhesins in the virulence of opportunistic fungal pathogens of human. Mycology. Taylor and Francis Ltd.; 2021. pp. 296–324.

Liu Y, Filler SG. Candida albicans Als3, a multifunctional adhesin and invasin. Eukaryot Cell. 2011. pp. 168–73.

Rosiana S, Zhang L, Kim GH, Revtovich AV, Uthayakumar D, Sukumaran A et al. Comprehensive genetic analysis of adhesin proteins and their role in virulence of candida albicans. Genetics. 2021;217.

Hoyer LL, Cota E. Candida albicans agglutinin-like sequence (als) family vignettes: a review of als protein structure and function. Front Microbiol. 2016;7:280

de Groot PWJ, Bader O, de Boer AD, Weig M, Chauhan N. Adhesins in human fungal pathogens: glue with plenty of stick. Eukaryot Cell. 2013. pp. 470–81.

Gupta SK, Osmanoglu Ö, Minocha R, Bandi SR, Bencurova E, Srivastava M, et al. Genome-wide scan for potential CD4 + T-cell vaccine candidates in Candida Auris by exploiting reverse vaccinology and evolutionary information. Front Med (Lausanne). 2022;9:1008527.

Singh S, Uppuluri P, Mamouei Z, Alqarihi A, Elhassan H, French S, et al. The NDV-3A vaccine protects mice from multidrug resistant Candida Auris infection. PLoS Pathog. 2019;15(8):e1007460.

Bing J, Guan Z, Zheng T, Zhang Z, Fan S, Ennis CL, et al. Clinical isolates of Candida Auris with enhanced adherence and biofilm formation due to genomic amplification of ALS4. PLoS Pathog. 2023;19(3):e1011239.

Horton MV, Holt AM, Nett JE. Mechanisms of pathogenicity for the emerging fungus Candida Auris. PLoS Pathog. Public Library of Science. 2023;19(12):e1011843.

Chechi JL, da Costa FAC, Figueiredo JM, de Souza CM, Valdez AF, Zamith-Miranda D, et al. Vaccine development for pathogenic fungi: current status and future directions. Expert Rev Vaccines. 2023;1136–53.

Kischkel B, Boniche-Alfaro C, Menezes I, de Rossi G, Angeli SA, de Almeida CB. SR, immunoproteomic and immunopeptidomic analyses of histoplasma capsulatum reveal promiscuous and conserved epitopes among fungi with vaccine potential. Front Immunol. 2021;12:764501.

Spellberg BJ, Ibrahim AS, Avanesian V, Fu Y, Myers C, Phan QT, et al. Efficacy of the anti-candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis. J Infect Dis. 2006;194(2):256–60. https://doi.org/10.1086/504691.

Schmidt CS, White CJ, Ibrahim AS, Filler SG, Fu Y, Yeaman MR, et al. NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults. Vaccine. 2012;30:7594–600.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Akhtar N, Joshi A, Kaushik V, Kumar M, Mannan MA. In-silico design of a multivalent epitope-based vaccine against Candida auris. Microb Pathog. 2021;155:104879.

Figueiredo ABC, Fonseca FL, Kuczera D, de Paiva Conte F, Arissawa M, Rodrigues ML, et al. Monoclonal antibodies against cell wall chitooligomers as accessory tools for the control of cryptococcosis. Antimicrob Agents Chemother. 2021;17;65(12):e0118121.

Rosario-colon J, Eberle K, Adams A, Courville E, Xin H. Candida cell‐surface‐specific monoclonal antibodies protect mice against candida auris invasive infection. Int J Mol Sci. 2021;22(11):6162.

Luo G, Ibrahim AS, Spellberg B, Nobile CJ, Mitchell AP, Fu Y. Candida albicans Hyr1p confers resistance to neutrophil killing and is a potential vaccine target. J Infect Dis. 2010;201:1718–28.

Article  PubMed  CAS  Google Scholar 

Singh S, Barbarino A, Youssef EG, Coleman D, Gebremariam T, Ibrahim AS. Protective efficacy of Anti-Hyr1p monoclonal antibody against systemic Candidiasis due to Multi-drug-resistant Candida auris. J Fungi. 2023;9(1):103.

Di Mambro T, Vanzolini T, Bruscolini P, Perez-Gaviro S, Marra E, Roscilli G et al. A new humanized antibody is effective against pathogenic fungi in vitro. Sci Rep. 2021;11(1):19500.

Marena GD, Ramos MA dos, Carvalho S, Junior GC, Resende JAP, Corrêa FA. I, et al. Natural product-based nanomedicine applied to fungal infection treatment: a review of the last 4 years. Phytotherapy Research. John Wiley and Sons Ltd; 2022. pp. 2710–45.

Marena GD, Carvalho GC, Ruiz-Gaitán A, Onisto GS, Bugalho BCM, Genezini LMV, et al. Potential activity of micafungin and amphotericin b co-encapsulated in